Posted by Michael Wonder on 15 Jul 2019
NICE recommends Skyrizi, Forxiga
15 July 2019 - NICE has recommended two new drugs on the NHS, AbbVie’s Skyrizi (risankizumab) and AstraZeneca’s Forxiga (dapagliflozin)
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
Skyrizi, a humanised immunoglobulin G1 monoclonal antibody, will be available for adult patients in England and Wales with plaque psoriasis, who have failed conventional systemic therapies.
